IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v6y2022i2d10.1007_s41669-021-00293-4.html
   My bibliography  Save this article

Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan

Author

Listed:
  • Imad Treish

    (Department of Pharmacy, Center for Drug Policy and Technology Assessment (CDPTA))

  • Abeer Al Rabayah

    (Department of Pharmacy, Center for Drug Policy and Technology Assessment (CDPTA))

  • Saad Jaddoua

    (Department of Pharmacy, Center for Drug Policy and Technology Assessment (CDPTA))

  • Haitham Tuffaha

    (The University of Queensland)

Abstract

Rising prices of novel cancer medications are increasing the economic burden from cancer in Jordan, risking the ability of cancer patients to access lifesaving and life-extending treatments. Furthermore, in the absence of a national health technology assessment (HTA) framework, medication prices in Jordan are set based on manufacturers’ pricing considerations and not a value proposition. In response to these challenges, King Hussein Cancer Center (KHCC), the de facto national cancer institute, developed a first-in-country, cancer-specific, cost-effectiveness threshold (CET) to aid institutional decision makers in approving only cost-effective medications. Over the past 10 years, cost-effectiveness analyses based on this CET have led to the introduction of > 70% of requested novel cancer medications after manufacturers agreed to lower prices, beyond registration prices, to meet the CET. Future work is warranted to empirically derive a CET for Jordan to better guide reimbursement decisions.

Suggested Citation

  • Imad Treish & Abeer Al Rabayah & Saad Jaddoua & Haitham Tuffaha, 2022. "Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan," PharmacoEconomics - Open, Springer, vol. 6(2), pages 137-145, March.
  • Handle: RePEc:spr:pharmo:v:6:y:2022:i:2:d:10.1007_s41669-021-00293-4
    DOI: 10.1007/s41669-021-00293-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-021-00293-4
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-021-00293-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:6:y:2022:i:2:d:10.1007_s41669-021-00293-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.